Related Experiment Video
Updated: Sep 4, 2026

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death
Published on: October 21, 2012
The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells
S Mahmoud A Najafi1, Zheng Li, Keishi Makino
1Department of Molecular and Cellular Oncology, Box 108, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Abstract:
The adenovirus-5 E1A gene encodes two main proteins of 289 and 243 amino acid residues from 13S and 12S mRNA, respectively. The E1A gene products function as transcriptional regulators and have anti-tumor activities. Despite the fact that E1A gene therapy has been tested in clinical trials, the molecular mechanism by which it suppresses tumor cell growth is still not completely understood. Here, we show that E1A increases the expression of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/CIP1), which inhibits cell growth. We further show that 13S E1A, but not 12S E1A, can transactivate the p21 promoter through Sp1 sites. Interestingly, the E1A-induced transactivation occurs only in cancer cells, not in normal cells. This study provides new insight into the links between E1A and the CDK inhibitor and may have important clinical implications.
Insights
Adenovirus-5 E1A proteins suppress tumor growth by increasing cyclin-dependent kinase inhibitor p21(WAF1/CIP1) expression. The 13S E1A protein specifically activates the p21 promoter in cancer cells, offering new therapeutic insights.
Area of Science:
- Molecular biology
- Cancer research
- Virology
Background:
- Adenovirus-5 E1A proteins are transcriptional regulators with anti-tumor properties.
- The precise mechanism of E1A-mediated tumor suppression is not fully elucidated.
- E1A gene therapy has shown promise in clinical trials.
Purpose of the Study:
- To investigate the molecular mechanism underlying E1A's anti-tumor activity.
- To determine the role of E1A in regulating cell growth inhibitors.
- To explore the differential activity of E1A isoforms on tumor cells.
Main Methods:
- Analysis of E1A protein expression from 13S and 12S mRNA.
- Assessing the impact of E1A on cyclin-dependent kinase (CDK) inhibitor p21(WAF1/CIP1) levels.
- Investigating E1A-mediated transactivation of the p21 promoter via Sp1 sites in cancer and normal cells.
Main Results:
- E1A significantly increases the expression of p21(WAF1/CIP1), a cell growth inhibitor.
- The 13S E1A isoform, but not the 12S isoform, transactivates the p21 promoter.
- This E1A-induced transactivation is specific to cancer cells and does not occur in normal cells.
Conclusions:
- E1A's tumor suppressive function is partly mediated by upregulating p21(WAF1/CIP1).
- The 13S E1A isoform plays a key role in this process through Sp1-dependent promoter activation in cancer cells.
- These findings provide novel insights into E1A's mechanism of action and potential clinical applications in cancer therapy.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

